Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: A national practice audit

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 11-12, 2012, Pages 1049-1056

  Hou, J K ^a,b   Kramer, J R ^a,b   Richardson, P ^a,b   Sansgiry, S ^a,b,c   El Serag, H B ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c South Central Mental Illness Research Education and Clinical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOMODULATING AGENT; MERCAPTOPURINE; METHOTREXATE; TIOGUANINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BONE MARROW SUPPRESSION; CAUCASIAN; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DATA ANALYSIS; DRUG MONITORING; ENTERITIS; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; HUMAN CELL; IMMUNOMODULATION; INDETERMINATE COLITIS; LEUKOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; ULCERATIVE COLITIS; VETERAN; AGE; GOVERNMENT; HEALTH CARE DELIVERY; LEUKOCYTE COUNT; LEUKOPENIA; METHODOLOGY; MIDDLE AGED; STANDARD; TREATMENT OUTCOME; UNITED STATES;

6-MERCAPTOPURINE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AZATHIOPRINE; DELIVERY OF HEALTH CARE; DRUG MONITORING; DRUG PRESCRIPTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MEDICAL AUDIT; METHOTREXATE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84875890217     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12075     Document Type: Article

References (24)

1. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulatortreated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051-63.
2. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112-24.
3. van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease-proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis 2011;43:270-6.
4. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5. (Pubitemid 23245359)
5. Gisbert JP, Gomollón F. Thiopurineinduced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008;103:1783-800.
6. Lewis JD, Abramson O, Pascua M, et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 2009;7:1195-201.
7. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30. (Pubitemid 30346978)
8. González-Lama Y, Bermejo F, López-Sanromán A; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU), et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011;34:544-54.
9. Mowat C, Cole A, Windsor A; IBD Section of the British Society of Gastroenterology, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
10. Lichtenstein GR, Hanauer SB. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83.
11. Lichtenstein GR, Abreu MT, Cohen R, American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-9. (Pubitemid 43374542)
12. Berwick DM. Controlling variation in health care: a consultation from Walter Shewhart. Med Care 1991;29:1212-25.
13. Hou JK, Kramer JR, Richardson P, et al. Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis. Inflamm Bowel Dis 2012;18:1011-7.
14. Thirumurthi S, Chowdhury R, Richardson P, et al. Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans. Dig Dis Sci 2010;55:2592-8.
15. Morgan RO, Petersen LA, Hasche JC, et al. VHA pharmacy use in veterans with Medicare drug coverage. Am J Manag Care 2009;15:e1-8.
16. Velayos FS, Liu L, Lewis JD, Allison JE, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology 2010;139:1511-8.
17. Wagnon JH, Leiman DA, Ayers GD, et al. Survey of gastroenterologists' awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: are the guidelines being used and what are the barriers to their use? Inflamm Bowel Dis 2009;15:1082-9.
18. Peyrin-Biroulet L, Oussalah A, Boucekkine T, et al. TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine. Gastroenterol Clin Biol 2009;33:23-30.
19. Kottachchi D, Yung D, Marshall JK. Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. Can J Gastroenterol 2009;23:613-7.
20. Kanwal F, Hoang T, Kramer J, et al. The performance of process measures in hepatitis C. Am J Gastroenterol 2012; doi: 10.1038/ajg.2012.201 [Epub ahead of print].
21. Kanwal F, Kramer JR, Buchanan P, et al. The quality of care provided to patients with cirrhosis and ascites in the department of veterans affairs. Gastroenterology 2012;143:70-7.
22. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA 1999;282:1458-65.
23. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis 2007;13:451-61. (Pubitemid 46668251)
24. French DD, Margo CE. Factors associated with the utilization of cataract surgery for veterans dually enrolled in Medicare. Mil Med 2012;177:752-6.